Need to Recalibrate Research Outcomes in Alzheimer's Disease: Focus on Neuropsychiatric Symptoms

Marco Canevelli, Matteo Cesari, Flaminia Lucchini, Martina Valletta, Michele Sabino, Eleonora Lacorte, Nicola Vanacore, Giuseppe Bruno

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objectives: To determine whether neuropsychiatric symptoms (NPSs) are adequately considered in clinical research on Alzheimer's disease (AD). Design: Systematic review. Setting: Randomized controlled trials (RCTs) recruiting individuals with AD and published during the last 10 years in 16 major general medicine, neurology, psychiatry, and geriatric psychiatry journals and RCTs registered on clinicaltrials.gov and currently enrolling individuals with AD. Participants: Individuals with AD. Measurements: Outcome measures adopted by the included studies. Results: Only 21.4% of the included studies identified through the bibliographic searches had measures of NPSs as a primary outcome. Only 17.7% of the studies retrieved on clinicaltrials.gov made a specific effort to test the effect of pharmacological or nonpharmacological interventions on NPSs. Conclusion: These findings show how rarely previous and current research on AD has considered NPSs as primary research targets. Although these symptoms are widely recognized as the most-stressful and -challenging manifestations of dementia, they are addressed much less often than other research targets.

Original languageEnglish
Pages (from-to)2071-2073
Number of pages3
JournalJournal of the American Geriatrics Society
Volume65
Issue number9
DOIs
Publication statusPublished - Sep 1 2017

Fingerprint

Alzheimer Disease
Outcome Assessment (Health Care)
Research
Randomized Controlled Trials
Geriatric Psychiatry
Neurology
Psychiatry
Dementia
Medicine
Pharmacology

Keywords

  • Alzheimer's disease
  • clinical research
  • neuropsychiatric symptoms
  • randomized controlled trials

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Need to Recalibrate Research Outcomes in Alzheimer's Disease : Focus on Neuropsychiatric Symptoms. / Canevelli, Marco; Cesari, Matteo; Lucchini, Flaminia; Valletta, Martina; Sabino, Michele; Lacorte, Eleonora; Vanacore, Nicola; Bruno, Giuseppe.

In: Journal of the American Geriatrics Society, Vol. 65, No. 9, 01.09.2017, p. 2071-2073.

Research output: Contribution to journalArticle

Canevelli, Marco ; Cesari, Matteo ; Lucchini, Flaminia ; Valletta, Martina ; Sabino, Michele ; Lacorte, Eleonora ; Vanacore, Nicola ; Bruno, Giuseppe. / Need to Recalibrate Research Outcomes in Alzheimer's Disease : Focus on Neuropsychiatric Symptoms. In: Journal of the American Geriatrics Society. 2017 ; Vol. 65, No. 9. pp. 2071-2073.
@article{a167b9b0bf5342a09ff2b9b0e06286a3,
title = "Need to Recalibrate Research Outcomes in Alzheimer's Disease: Focus on Neuropsychiatric Symptoms",
abstract = "Objectives: To determine whether neuropsychiatric symptoms (NPSs) are adequately considered in clinical research on Alzheimer's disease (AD). Design: Systematic review. Setting: Randomized controlled trials (RCTs) recruiting individuals with AD and published during the last 10 years in 16 major general medicine, neurology, psychiatry, and geriatric psychiatry journals and RCTs registered on clinicaltrials.gov and currently enrolling individuals with AD. Participants: Individuals with AD. Measurements: Outcome measures adopted by the included studies. Results: Only 21.4{\%} of the included studies identified through the bibliographic searches had measures of NPSs as a primary outcome. Only 17.7{\%} of the studies retrieved on clinicaltrials.gov made a specific effort to test the effect of pharmacological or nonpharmacological interventions on NPSs. Conclusion: These findings show how rarely previous and current research on AD has considered NPSs as primary research targets. Although these symptoms are widely recognized as the most-stressful and -challenging manifestations of dementia, they are addressed much less often than other research targets.",
keywords = "Alzheimer's disease, clinical research, neuropsychiatric symptoms, randomized controlled trials",
author = "Marco Canevelli and Matteo Cesari and Flaminia Lucchini and Martina Valletta and Michele Sabino and Eleonora Lacorte and Nicola Vanacore and Giuseppe Bruno",
year = "2017",
month = "9",
day = "1",
doi = "10.1111/jgs.14989",
language = "English",
volume = "65",
pages = "2071--2073",
journal = "Journal of the American Geriatrics Society",
issn = "0002-8614",
publisher = "Blackwell Publishing Inc.",
number = "9",

}

TY - JOUR

T1 - Need to Recalibrate Research Outcomes in Alzheimer's Disease

T2 - Focus on Neuropsychiatric Symptoms

AU - Canevelli, Marco

AU - Cesari, Matteo

AU - Lucchini, Flaminia

AU - Valletta, Martina

AU - Sabino, Michele

AU - Lacorte, Eleonora

AU - Vanacore, Nicola

AU - Bruno, Giuseppe

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Objectives: To determine whether neuropsychiatric symptoms (NPSs) are adequately considered in clinical research on Alzheimer's disease (AD). Design: Systematic review. Setting: Randomized controlled trials (RCTs) recruiting individuals with AD and published during the last 10 years in 16 major general medicine, neurology, psychiatry, and geriatric psychiatry journals and RCTs registered on clinicaltrials.gov and currently enrolling individuals with AD. Participants: Individuals with AD. Measurements: Outcome measures adopted by the included studies. Results: Only 21.4% of the included studies identified through the bibliographic searches had measures of NPSs as a primary outcome. Only 17.7% of the studies retrieved on clinicaltrials.gov made a specific effort to test the effect of pharmacological or nonpharmacological interventions on NPSs. Conclusion: These findings show how rarely previous and current research on AD has considered NPSs as primary research targets. Although these symptoms are widely recognized as the most-stressful and -challenging manifestations of dementia, they are addressed much less often than other research targets.

AB - Objectives: To determine whether neuropsychiatric symptoms (NPSs) are adequately considered in clinical research on Alzheimer's disease (AD). Design: Systematic review. Setting: Randomized controlled trials (RCTs) recruiting individuals with AD and published during the last 10 years in 16 major general medicine, neurology, psychiatry, and geriatric psychiatry journals and RCTs registered on clinicaltrials.gov and currently enrolling individuals with AD. Participants: Individuals with AD. Measurements: Outcome measures adopted by the included studies. Results: Only 21.4% of the included studies identified through the bibliographic searches had measures of NPSs as a primary outcome. Only 17.7% of the studies retrieved on clinicaltrials.gov made a specific effort to test the effect of pharmacological or nonpharmacological interventions on NPSs. Conclusion: These findings show how rarely previous and current research on AD has considered NPSs as primary research targets. Although these symptoms are widely recognized as the most-stressful and -challenging manifestations of dementia, they are addressed much less often than other research targets.

KW - Alzheimer's disease

KW - clinical research

KW - neuropsychiatric symptoms

KW - randomized controlled trials

UR - http://www.scopus.com/inward/record.url?scp=85021809258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021809258&partnerID=8YFLogxK

U2 - 10.1111/jgs.14989

DO - 10.1111/jgs.14989

M3 - Article

C2 - 28682462

AN - SCOPUS:85021809258

VL - 65

SP - 2071

EP - 2073

JO - Journal of the American Geriatrics Society

JF - Journal of the American Geriatrics Society

SN - 0002-8614

IS - 9

ER -